← Back to Clinical Trials
Recruiting NCT04336644

Continuous Versus Intermittent cARdiac Electrical moNitorinG

Trial Parameters

Condition Torsades de Pointe Caused by Drug
Sponsor Washington University School of Medicine
Study Type INTERVENTIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-11-21
Completion 2026-12-31
Interventions
BodyGuardian Mini Plus

Brief Summary

The purpose of this study is to validate the continuous patch monitoring system to evaluate cardiac arrhythmias in patients receiving drugs that can cause cardiac complications and compare the continuous patch system with standard electrocardiograms (ECGs).

Eligibility Criteria

Inclusion Criteria: * Diagnosis of acute promyelocytic leukemia (APL) and being initiated on standard of care arsenic trioxide OR Diagnosis of solid tumor and being initiated on standard of care capecitabine (alone or as part of combination treatment) OR Diagnosis of solid tumor and being initiated on standard of care ribociclib (alone or as part of combination treatment) * At least 18 years of age. * No allergy to adhesive patches. * Able to understand and willing to sign an IRB-approved written informed consent document. Exclusion Criteria: * Younger than 18 years of age * Allergy to adhesive patches

Related Trials